: J&J: ‘Tripledemic’ fueled direct for Motrin and Tylenol

As cases of COVID, influenza and respiratory syncytial virus, or RSV, surged in a tumble as partial of a “tripledemic” in a U.S., direct for cold drugs translated to a good entertain for Johnson Johnson’s JNJ consumer health business.

JJ’s over-the-counter division, that includes a pain reliever Motrin and a allergy medicine Zyrtec, had sales of $1.57 billion in a final 3 months of 2022, adult from $1.37 billion in a same entertain of a prior year. It also kick a FactSet accord of $1.4 billion. (The company…

This entry was posted in Featured Articles and tagged . Bookmark the permalink.